Observational Study
Copyright ©The Author(s) 2024.
World J Gastrointest Surg. Nov 27, 2024; 16(11): 3520-3530
Published online Nov 27, 2024. doi: 10.4240/wjgs.v16.i11.3520
Table 2 186 patients with pseudomyxoma were treated with cell reduction combined with intraperitoneal hyperthermic chemotherapy
Incidence of complications
n (%)
Death 30 days after surgery5 (2.7)
Death 90 days after surgery8 (4.3)
Further surgery is required3 (1.6)
Grade III-IN complications80 (43.0)
    Gastrointestinal anastomotic leakage4 (2.2)
    Urinary system complications (ureteral injury, urinary leakage, etc.)1 (0.5)
    Abdominal bleeding4 (2.2)
    Abdominal infection8 (4.3)
    Wound infection2 (1.1)
    Sepsis or sepsis1 (0.5)
    Urinary tract infection1 (0.5)
    Ascites4 (2.2)
    Pneumonia10 (5.4
    Pneumothorax2 (1.1)
    Cardiac insufficiency or heart failure2 (1.1)
    Renal insufficiency1 (0.5)
    Hepatic insufficiency19 (10.2)
    Septic shock2 (1.1)
    Hemorrhagic shock2 (1.1)
    Albumin reduction14 (7.5)
    Hemoglobin reduction51 (27.4)
    Thrombocytopenia2 (1.1)
    Electrolyte disturbance21 (11.6)
    Coagulopathy11 (5.9)